Literature DB >> 2787398

Leukoplakia and incidence of oral cancer.

P C Gupta1.   

Abstract

Reports from India showing comparatively lower prevalence rates of oral leukoplakia and lower malignant transformation rates than in western countries appear paradoxical because of high incidence rates of oral cancer in India. On a closer examination of available data however, it becomes clear that there is no inconsistency.

Entities:  

Mesh:

Year:  1989        PMID: 2787398     DOI: 10.1111/j.1600-0714.1989.tb00725.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  6 in total

Review 1.  Oral premalignant lesions: from a clinical perspective.

Authors:  Teruo Amagasa; Masashi Yamashiro; Narikazu Uzawa
Journal:  Int J Clin Oncol       Date:  2011-01-12       Impact factor: 3.402

2.  Three-year follow-up of oral leukoplakia after neodymium:yttrium aluminum garnet (Nd:YAG) laser surgery.

Authors:  V Vivek; R S Jayasree; Anita Balan; K T Sreelatha; A K Gupta
Journal:  Lasers Med Sci       Date:  2007-10-27       Impact factor: 3.161

3.  Circulating Immune complexes (CIC) as marker for disease progress in oral cancer.

Authors:  Cynthia Jane; A V Nerurkar; F R Karjodkar
Journal:  Indian J Clin Biochem       Date:  2007-09

4.  Circulating immune complexes and trace elements (Copper, Iron and Selenium) as markers in oral precancer and cancer : a randomised, controlled clinical trial.

Authors:  Sunali S Khanna; Freny R Karjodkar
Journal:  Head Face Med       Date:  2006-10-16       Impact factor: 2.151

5.  Telomerase in saliva: An assistant marker for oral squamous cell carcinoma.

Authors:  Fahad Mansoor Samadi; Shaista Suhail; Manjari Sonam; Mohammad Kaleem Ahmad; Shaleen Chandra; Mohammad Saleem
Journal:  J Oral Maxillofac Pathol       Date:  2019 May-Aug

6.  Immunological and biochemical markers in oral carcinogenesis: the public health perspective.

Authors:  Sunali Khanna
Journal:  Int J Environ Res Public Health       Date:  2008-12       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.